The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Angiogenesis and Its Therapeutic Opportunities
Open accessAbstract
Angiogenesis plays critical roles in human physiology that range from reproduction and fetal growth to wound healing and tissue repair. The sophisticated multistep process is tightly regulated in a spatial and temporal manner by “on-off switch signals” between angiogenic factors, extracellular matrix components, and endothelial cells. Uncontrolled angiogenesis may lead to several angiogenic disorders, including vascular insufficiency (myocardial or critical limb ischemia) and vascular overgrowth (hemangiomas, vascularized tumors, and retinopathies). Thus, numerous therapeutic opportunities can be envisaged through the successful understanding and subsequent manipulation of angiogenesis. Here, we review the clinical implications of angiogenesis and discuss pro- and antiangiogenic agents that offer potential therapy for cancer and other angiogenic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Wound Healing--Aiming for Perfect Skin Regeneration
Martin, P. (1997) · Science · doi:10.1126/science.276.5309.75 · Cited by 4,804
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628
Folkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,491
O'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345
Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor
Heldin, C.-H., & Westermark, B. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1283 · Cited by 2,496
Clinical Applications of Research on Angiogenesis
Folkman, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332608 · Cited by 2,264
THE HEPARIN-BINDING (FIBROBLAST) GROWTH FACTOR FAMILY OF PROTEINS
Burgess, W. H., & Maciag, T. (1989) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.58.070189.003043 · Cited by 1,928
Holmgren, L., O'Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,878
Vascular Endothelial Growth Factor and Angiogenesis
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.3 · Cited by 1,824
Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.
Gomez, D. E., Alonso, D. F., Yoshiji, H., & Thorgeirsson, U. P. (1997) · PubMed · Cited by 1,508
Regulation of matrix metalloproteinase expression in tumor invasion
Westermarck, J., & Kähäri, V. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.8.781 · Cited by 1,494
Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Science · doi:10.1126/science.7521539 · Cited by 1,438
Age-related macular degeneration
Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379
Activation mechanisms of matrix metalloproteinases.
Nagase, H. (1997) · PubMed · Cited by 1,119
Interferon Alfa-2a Therapy for Life-Threatening Hemangiomas of Infancy
Ezekowitz, R. A. B., Mulliken, J. B., & Folkman, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205283262203 · Cited by 1,071
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Pearce, C. L., Templeman, C., Rossing, M. A., Lee, A., Near, A. M., Webb, P. M., Nagle, C. M., Doherty, J. A., Cushing-Haugen, K. L., Wicklund, K. G., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70404-1 · Cited by 939
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G., & Goldberg, M. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10595 · Cited by 892
Pepper, M. S., Ferrara, N., Orci, L., & Montesano, R. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)92277-5 · Cited by 858
Miller, J. W., Adamis, A. P., Shima, D. T., D'Amore, P. A., Moulton, R. S., O'Reilly, M. S., Folkman, J., Dvorak, H. F., Brown, L. F., & Berse, B. (1994) · PubMed · Cited by 810
Role of the Matrix Metalloproteinase and Plasminogen Activator–Plasmin Systems in Angiogenesis
Pepper, M. S. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0701.093685 · Cited by 777
Angiogenesis: regulators and clinical applications
Liekens, S., De Clercq, E., & Neyts, J. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00529-3 · Cited by 748
Transforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall integrity
Pepper, M. S. (1997) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(96)00048-2 · Cited by 724
The codependence of angiogenesis and chronic inflammation
Jackson, J. R., Seed, M. P., Kircher, C. H., Willoughby, D. A., & Winkler, J. D. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.6.9194526 · Cited by 694
Sleijfer, S., Ray-Coquard, I., Papai, Z., Le Cesne, A., Scurr, M., Schöffski, P., Collin, F., Pandite, L., Marreaud, S., De Brauwer, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3223 · Cited by 679
Haggstrom, A. N., Drolet, B. A., Baselga, E., Chamlin, S. L., Garzon, M. C., Horii, K. A., Lucky, A. W., Mancini, A. J., Metry, D. W., Newell, B., et al. (2006) · Pediatrics · doi:10.1542/peds.2006-0413 · Cited by 619
Jw, M. (1994) · UCL Discovery (University College London) · Cited by 584
FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets
Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., & Pazdur, R. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-303 · Cited by 581
Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
Shih, T., & Lindley, C. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.015 · Cited by 521
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, K. J., & Verheul, H. M. W. (2010) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 501
Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
Sgadari, C., Angiolillo, A., & Tosato, G. (1996) · Blood · doi:10.1182/blood.v87.9.3877.bloodjournal8793877 · Cited by 469
Nguyen, M., Watanabe, H., Budson, A. E., Richie, J. P., Hayes, D. F., & Folkman, J. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.5.356 · Cited by 464
Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus: An Expert Panel Summary
Simons, M., Bonow, R. O., Chronos, N. A., Cohen, D. J., Giordano, F. J., Hammond, H. K., Laham, R. J., Li, W., Pike, M., Sellke, F. W., et al. (2000) · Circulation · doi:10.1161/01.cir.102.11.e73 · Cited by 459
FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets
Cohen, M. H., Johnson, J. R., Chen, Y.-F., Sridhara, R., & Pazdur, R. (2005) · The Oncologist · doi:10.1634/theoncologist.10-7-461 · Cited by 445
Kähäri, V.-M., & Saarialho-Kere, U. (1999) · Annals of Medicine · doi:10.3109/07853899909019260 · Cited by 408
Quantitative angiogenesis assays: Progress and problems
Jain, R. K., Schlenger, K., Hockel, M., & Yuan, F. (1997) · Nature Medicine · doi:10.1038/nm1197-1203 · Cited by 385
Mast cells and angiogenesis: Review article
Norrby, K. (2002) · APMIS · doi:10.1034/j.1600-0463.2002.100501.x · Cited by 381
Yoshiji, H., Gomez, D. E., Shibuya, M., & Thorgeirsson, U. P. (1996) · PubMed · Cited by 369
Conn, G., Bayne, M. L., Soderman, D. D., Kwok, P. W., Sullivan, K. A., Palisi, T. M., Hope, D. A., & Thomas, K. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2628 · Cited by 355
Plasminogen Activators and Matrix Metalloproteinases in Angiogenesis
Mignatti, P., & Rifkin, D. B. (1996) · Enzyme and Protein · doi:10.1159/000468621 · Cited by 330
Seno, H., Oshima, M., Ishikawa, T., Oshima, H., Takaku, K., Chiba, T., Narumiya, S., & Taketo, M. M. (2002) · PubMed · Cited by 327
Angiogenesis: a Dynamic Balance of Stimulators and Inhibitors
Iruela-Arispe, L. M., & Dvorak, H. F. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657610 · Cited by 311
Angiogenesis in human coronary atherosclerotic plaques.
O’Brien, E. R., Garvin, M. R., Dev, R., Stewart, D. K., Hinohara, T., Simpson, J. B., & Schwartz, S. M. (1994) · PubMed · Cited by 302
Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis.
Daniel, T. O., Liu, H., Morrow, J. D., et al. (1999) · PubMed · Cited by 295
In vivo models of angiogenesis
Norrby, K. (2006) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2006.tb00423.x · Cited by 286
Discovery of a New Mechanism and Development of Angiogenic Therapy That Accelerates Healing
FOLKMAN, J., SZABO, S., STOVROFF, M., MCNEIL, P., LI, W., & SHING, Y. (1991) · Annals of Surgery · doi:10.1097/00000658-199110000-00006 · Cited by 280
Struman, I., Bentzien, F., Lee, H., Mainfroid, V., D’Angelo, G., Goffin, V., Weiner, R. I., & Martial, J. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1246 · Cited by 279
Anti-vascular endothelial growth factor therapy for ocular neovascular disease
Andreoli, C. M., & Miller, J. W. (2007) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e3282f0ca54 · Cited by 274
Dinney, C. P., Bielenberg, D. R., Perrotte, P., Reich, R., Eve, B. Y., BUCANA, C. D., & Fidler, I. J. (1998) · PubMed · Cited by 271
Okada, F., Rak, J. W., Croix, B. S., Lieubeau, B., Kaya, M., Roncari, L., Shirasawa, S., Sasazuki, T., & Kerbel, R. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3609 · Cited by 267
Fernandez, M., Vizzutti, F., Garcia-Pagan, J. C., Rodes, J., & Bosch, J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.12.012 · Cited by 259
Pytowski, B., Goldman, J., Persaud, K., Wu, Y., Witte, L., Hicklin, D. J., Skobe, M., Boardman, K. C., & Swartz, M. A. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji003 · Cited by 248
Rock, E. P., Goodman, V., Jiang, J. X., Mahjoob, K., Verbois, S. L., Morse, D., Dagher, R., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-107 · Cited by 247
Klagsbrun, M., & Moses, M. A. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80081-7 · Cited by 237
Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agents
Teicher, B. A., Holden, S. A., Ara, G., Sotomayor, E. A., Huang, Z. D., Chen, Y., & Brem, H. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570624 · Cited by 231
Volm, M., Koomägi, R., & Mattern, J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970220)74:1<64::aid-ijc11>3.0.co;2-i · Cited by 230
Los, M., Roodhart, J. M. L., & Voest, E. E. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-443 · Cited by 229
Li, V. W., Yu AB, C., Folkman, J., Scott, R. M., McL Black, P., Folkerth, R., Barnes, P., Sallan, S. E., Rupnick, M., & Watanabe, H. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91280-7 · Cited by 228
Therapeutic Angiogenesis With Basic Fibroblast Growth Factor: Technique and Early Results
Sellke, F. W., Laham, R. J., Edelman, E. R., Pearlman, J. D., & Simons, M. (1998) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(98)00340-3 · Cited by 215
Assays for angiogenesis: A review
Auerbach, R., Auerbach, W., & Polakowski, I. (1991) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(91)90038-n · Cited by 202
Gately, S. T., Twardowski, P., Stack, M. S., Patrick, M., Boggio, L. N., Cundiff, D. L., Schnaper, H. W., Madison, L. D., Volpert, O. V., Bouck, N., et al. (1996) · PubMed · Cited by 197
Angiogenesis: Models and Modulators
Cockerill, G. W., Gamble, J. R., & Vadas, M. A. (1995) · International Review of Cytology · doi:10.1016/s0074-7696(08)62106-3 · Cited by 195
Controlling the vasculature: Angiogenesis, anti-angiogenesis and vascular targeting of gene therapy
Fan, T.-P. D., Jagger, R., & Bicknell, R. (1995) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)88979-8 · Cited by 192
Hayes, A. J., Huang, W.-Q., Mallah, J., Yang, D., Lippman, M. E., & Li, L.-Y. (1999) · Microvascular Research · doi:10.1006/mvre.1999.2179 · Cited by 190
Angiogenesis inhibition suppresses collagen arthritis.
Peacock, D. J., Banquerigo, M. L., & Brahn, E. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.4.1135 · Cited by 188
Nickoloff, B. J., Mitra, R. S., Varani, J., Dixit, V. M., & Polverini, P. J. (1994) · PubMed Central · Cited by 186
Moy, B., Kirkpatrick, P. N., Kar, S., & Goss, P. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2332 · Cited by 180
The Rationale and Future Potential of Angiogenesis Inhibitors in Neoplasia
Gasparini, G. (1999) · Drugs · doi:10.2165/00003495-199958010-00003 · Cited by 160
Colpaert, C. G., Vermeulen, P. B., Benoy, I., Soubry, A., Van Roy, F., van Beest, P., Goovaerts, G., Dirix, L. Y., Van Dam, P., Fox, S. B., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600807 · Cited by 159
FDA Approves Sorafenib for Patients With Inoperable Liver Cancer
Lang, L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.037 · Cited by 159
The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer
Arenberg, D. A., Polverini, P. J., Kunkel, S. L., Shanafelt, A., Hesselgesser, J., Horuk, R., & Strieter, R. M. (1997) · Journal of Leukocyte Biology · doi:10.1002/jlb.62.5.554 · Cited by 158
McNeel, D. G., Eickhoff, J. C., Lee, F. T., King, D. M., Alberti, D. B., Thomas, J. P., Friedl, A., Kolesar, J., Marnocha, R., Volkman, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0262 · Cited by 156
Tomisawa, M., Tokunaga, T., Oshika, Y., Tsuchida, T., Fukushima, Y., Sato, H., Kijima, H., Yamazaki, H., Ueyama, Y., Tamaoki, N., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00278-0 · Cited by 147
Regulation of Endothelial Cell Growth, Architecture, and Matrix Synthesis by TGF-β
Roberts, A. B., & Sporn, M. B. (1989) · American Review of Respiratory Disease · doi:10.1164/ajrccm/140.4.1126 · Cited by 141
Antiangiogenic tumour therapy: will it work?
Augustin, H. G. (1998) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(98)01211-5 · Cited by 138
The Role of Therapeutic Angiogenesis in Tissue Repair and Regeneration
Li, W. W., Talcott, K. E., Zhai, A. W., Kruger, E. A., & Li, V. W. (2005) · Advances in Skin & Wound Care · doi:10.1097/00129334-200511000-00013 · Cited by 126
Janne, P. A., von Pawel, J., Cohen, R. B., Crinò, L., Butts, C. A., Olson, S. S., Eiseman, I. A., Chiappori, A., Yeap, B. Y., Lenehan, P. F., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.1336 · Cited by 126
Tumor angiogenesis—new drugs on the block
Brower, V. (1999) · Nature Biotechnology · doi:10.1038/13654 · Cited by 125
Posey, J. A., Ng, T. C., Yang, B., Khazaeli, M. B., Carpenter, M., Fox, F. E., Needle, M., Waksal, H. W., & LoBuglio, A. F. (2003) · PubMed · Cited by 119
Sowter, H., Corps, A. N., Evans, A. L., Clark, D. E., Jones, D. S., & Smith, S. K. (1997) · PubMed · Cited by 112
Campa, C., Costagliola, C., Incorvaia, C., Sheridan, C., Semeraro, F., Nadai, K. D., Sebastiani, A., & Parmeggiani, F. (2010) · Mediators of Inflammation · doi:10.1155/2010/546826 · Cited by 102
Angiogenic macrophages produce the angiogenic inhibitor thrombospondin 1.
DiPietro, L. A., & Polverini, P. J. (1993) · PubMed Central · Cited by 101
Onimaru, M., Yonemitsu, Y., Tanii, M., Nakagawa, K., Masaki, I., Okano, S., Ishibashi, H., Shirasuna, K., Hasegawa, M., & Sueishi, K. (2002) · Circulation Research · doi:10.1161/01.res.0000043281.66969.32 · Cited by 96
Role of soluble mediators in angiogenesis
Bussolino, F., Albini, A., Camussi, G., Presta, M., Viglietto, G., Ziehe, M., & Persico, G. M. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00390-5 · Cited by 94
Actions of TNF and INF-γ on Angiogenesis In Vitro
Sato, N., Nariuchi, H., Tsuruoka, N., Nishihara, T., Beitz, J. G., Calabresi, P., & Frackelton, A. R. (1990) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12874809 · Cited by 88
Sovak, M. A., Arsura, M., Zanieski, G., Kavanagh, K. T., & Sonenshein, G. E. (1999) · PubMed · Cited by 87
Rosen, E. M., Lamszus, K., Laterra, J., Polverini, P. J., Rubin, J. S., & Goldberg, I. D. (2007) · Novartis Foundation symposium · doi:10.1002/9780470515457.ch14 · Cited by 85
Moore, B. B., Keane, M. P., Addison, C., Arenberg, D. A., Strieter, R. M., & Koch, A. (1998) · Journal of Investigative Medicine · doi:10.1177/170882679804600406 · Cited by 79
Sandler, A. B., & Herbst, R. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0796 · Cited by 70
7‐Deazaxanthine, a novel prototype inhibitor of thymidine phosphorylase
Balzarini, J., Gamboa, A. E., Esnouf, R. M., et al. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01271-x · Cited by 69
Anti-Angiogenic Therapeutic Drugs for Treatment of Human Cancer
Wu, H., Huang, C.-T., & Chang, D.-K. (2008) · Cited by 67
Hamby, J. M., & Showalter, H. D. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00053-9 · Cited by 66
Lee, S.-W., Won, J.-Y., Lee, H., Lee, H.-J., Youn, S., Lee, J.-Y., Cho, C., Cho, H., Oh, S., Chae, I., et al. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00106 · Cited by 64
Neely, K. A., & Gardner, T. W. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65607-6 · Cited by 62
Dalès, J.-P., Garcia, S., Carpentier, S., Andrac, L., Ramuz, O., Lavaut, M. N., Allasia, C., Bonnier, P., & Charpin, C. (2004) · Human Pathology · doi:10.1016/j.humpath.2003.10.008 · Cited by 59
Kirshner, R. (1994) · Scientific American · doi:10.1038/scientificamerican1094-58 · Cited by 57
Models for Studying Angiogenesis in Vivo
Ribatti, D., & Vacca, A. (1999) · The International Journal of Biological Markers · doi:10.1177/172460089901400403 · Cited by 54
Vascular Endothelial Growth Factor Molecular and Biological Aspects
Ferrara, N., & Gerber, H. P. (1999) · Advances in organ biology · doi:10.1016/s1569-2590(08)60162-7 · Cited by 44
Shiff, S. J., & Rigas, B. (1999) · Nature Medicine · doi:10.1038/70909 · Cited by 37
Antiangiogenic Therapy for Glioma
Cea, V., Sala, C., & Verpelli, C. (2012) · Journal of Signal Transduction · doi:10.1155/2012/483040 · Cited by 36
Angiogenin, a potent mediator of angiogenesis. Biological, biochemical and structural properties.
Badet, J. (1999) · PubMed · Cited by 34
Factores de crecimiento para la angiogénesis terapéutica en las enfermedades cardiovasculares
Vale, P. R., Losordo, D. W., Symes, J. F., et al. (2001) · Revista Española de Cardiología · doi:10.1016/s0300-8932(01)76480-9 · Cited by 25
Sfiridaki, K., Pappa, C. A., Tsirakis, G., Kanellou, P., Kaparou, M., Stratinaki, M., Sakellaris, G., Kontakis, G. M., & Alexandrakis, M. G. (2011) · Mediators of Inflammation · doi:10.1155/2011/867576 · Cited by 23
Cited by
FOXO Signaling Pathways as Therapeutic Targets in Cancer
Farhan, M., Wang, H., Gaur, U., Little, P. J., Xu, J., & Zheng, W. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.20052 · Cited by 533
Zhang, B., Wu, X., Zhang, X., Sun, Y., Yan, Y., Shi, H., Zhu, Y., Wu, L., Pan, Z., Zhu, W., et al. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0267 · Cited by 477
FOXO transcription factors in cancer development and therapy
Coomans de Brachène, A., & Demoulin, J.-B. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2112-y · Cited by 284
Zhang, J., Chen, C., Hu, B., Niu, X., Liu, X., Zhang, G., Zhang, C., Li, Q., & Wang, Y. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.15514 · Cited by 278
Molecular mechanism of VEGF and its role in pathological angiogenesis
Ahmad, A., & Nawaz, M. I. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30344 · Cited by 260
Metadata
- Authors
- Yoo, S. Y., & Kwon, S. M.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2013
- Volume
- 2013
- Pages
- 1-11
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- OpenAlex
- W2137297789
- Cited by
- 259
- References
- 108
- FWCI
- 7.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.